DISRUPTIVE ADDED VALUE

UNIQUE APPROACH TO EVALUATE EFFICACY OF NOVEL THERAPEUTICS IN RECORD TIME

The pharmaceutical industry is under increased pressure to advance the development of new therapies in a fast and efficient manner, whilst ensuring the safety and quality of data.

ARENSIA’s playing field

The PROOF OF CONCEPT phase, particularly the "first-in-patient" clinical trials (Phase IB or IIA), is critical in the drug development process. It detects the initial efficacy signal of new therapies (compounds) in the targeted patient population. Data from these trials determine whether to continue or halt research of the respective new compound before significant investments in later phases of drug development.

Industry challenge

The growing demands for sophisticated Phase I/II PROOF OF CONCEPT protocols with innovative compounds in clinical trials require expert, dedicated research staff and facilities. However, typical clinical trial sites often lack dedicated personnel and expertise, forcing pharmaceutical companies to involve multiple sites to complete their trials. This results in high costs, delays, and quality issues for PROOF-OF-CONCEPT trials with relatively low patient numbers (12 to 200).

ARENSIA solution

At ARENSIA, we have addressed industry needs by establishing a proprietary network of research clinics in 8 countries over the past decade, spanning various therapeutic areas.

All ARENSIA Clinics are exclusively dedicated to expediting PROOF OF CONCEPT trials, ensuring the highest safety standards for patients and data quality.

Typical clinical trial sites encounter challenges like overcrowded schedules, insufficient staff, and prolonged contract negotiations. In contrast, ARENSIA Clinics achieve significant time reductions through unparalleled recruiting performance. By concentrating efforts on a select number of ARENSIA's research-dedicated clinics instead of a high number of clinical trial sites, we achieve a budget reduction of at least 50% for Phase IB/IIA PROOF-OF-CONCEPT trials.

Our 93% repeat business underscores that ARENSIA delivers a disruptive breakthrough in time and cost, fostering continuous growth and collaborations with leading pharmaceutical companies, biotechs, and global CROs